EXACT Sciences Co. (EXAS) Given Average Recommendation of “Buy” by Brokerages

Shares of EXACT Sciences Co. (NASDAQ:EXAS) have been given a consensus rating of “Buy” by the eighteen brokerages that are covering the firm, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $52.74.

A number of equities analysts recently weighed in on the stock. William Blair reiterated a “buy” rating on shares of EXACT Sciences in a research report on Wednesday, January 10th. Robert W. Baird lifted their price objective on shares of EXACT Sciences from $49.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 31st. Jefferies Group lifted their price objective on shares of EXACT Sciences to $60.00 and gave the company a “buy” rating in a research report on Tuesday, October 31st. Benchmark reiterated a “buy” rating and issued a $60.00 price objective (up from $50.00) on shares of EXACT Sciences in a research report on Tuesday, October 31st. Finally, Bank of America lifted their price objective on shares of EXACT Sciences from $56.00 to $58.00 and gave the company a “buy” rating in a research report on Tuesday, October 31st.

EXACT Sciences (EXAS) traded down $0.60 during trading hours on Friday, reaching $49.00. 2,040,937 shares of the company were exchanged, compared to its average volume of 3,040,000. EXACT Sciences has a 1 year low of $18.09 and a 1 year high of $63.60. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01. The stock has a market cap of $5,800.00, a price-to-earnings ratio of -42.61 and a beta of 0.58.

In other EXACT Sciences news, insider Kevin T. Conroy sold 134,057 shares of the business’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $59.50, for a total transaction of $7,976,391.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin T. Conroy sold 137,805 shares of the business’s stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $59.14, for a total transaction of $8,149,787.70. Following the sale, the chief executive officer now owns 967,867 shares in the company, valued at $57,239,654.38. The disclosure for this sale can be found here. Insiders have sold a total of 800,499 shares of company stock worth $44,083,803 over the last 90 days. Insiders own 4.00% of the company’s stock.

Several large investors have recently added to or reduced their stakes in EXAS. C M Bidwell & Associates Ltd. acquired a new position in shares of EXACT Sciences during the 4th quarter worth $117,000. Krilogy Financial LLC raised its stake in shares of EXACT Sciences by 1,460.0% during the 2nd quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after buying an additional 3,650 shares during the last quarter. Crow Point Partners LLC acquired a new position in shares of EXACT Sciences during the 4th quarter worth $145,000. Oppenheimer Asset Management Inc. raised its stake in shares of EXACT Sciences by 2,925.7% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock worth $150,000 after buying an additional 3,072 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of EXACT Sciences during the 3rd quarter worth $183,000. 82.02% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2018/02/03/exact-sciences-co-exas-given-average-recommendation-of-buy-by-brokerages.html.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply